Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis.
Deletion of chromosome 13q is believed to be an adverse prognostic marker in patients with multiple myeloma (MM). Interphase fluorescence in situ hybridization (I-FISH) is the method of choice for detection of chromosome 13q deletion (del13q). However, I-FISH has high false-positive rates attributed to a low percentage of plasma cells (PC), which are responsible for MM, in bone marrow (BM) samples from MM patients. In an attempt to overcome this problem, combined morphologic and I-FISH analyses were performed by a unique system that allows rapid automatic scanning of a large number of cells with simultaneous determination of the lineage of specific cells carrying del13q. The percentage of PC with del13q in BM samples from 40 MM patients was calculated. In addition, we established a useful prognostic ratio defined as the number of PC with del13q divided by the number of non-PC with del13q (PDP/PDNP), which may help to precisely define the putative role of del13q in prediction response of MM patients to new therapeutic compounds. We suggest this technique as a novel sensitive and specific method for detection of del13q in a minor PC population of MM patients.
Hardan
Izhar
I
Department of Bone Marrow Transplantation, Hematology and the Sheba Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Rothman
Rachel
R
Gelibter
Alain
A
Cohen
Ninette
N
Shimoni
Avichai
A
Sokolovsky
Maya
M
Reichart
Malka
M
Ishoev
Galina
G
Amariglio
Ninette
N
Rechavi
Gideon
G
Nagler
Arnon
A
Trakhtenbrot
Luba
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000648:ultrastructure*; D019070:Cell Lineage; D002872:Chromosome Deletion; D002882:Chromosomes, Human, Pair 13; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D007091:Image Processing, Computer-Assisted; D017404:In Situ Hybridization, Fluorescence; D007399:Interphase; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D012680:Sensitivity and Specificity; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin